{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:46:52Z","timestamp":1771930012429,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Combined BRAF\/MEK-inhibition constitutes a relevant treatment option for BRAF-mutated advanced melanoma. The prospective, non-interventional COMBI-r study assessed the effectiveness and tolerability of the BRAF-inhibitor dabrafenib combined with the MEK-inhibitor trametinib in patients with advanced melanoma under routine clinical conditions. Progression-free survival (PFS) was the primary objective, and secondary objectives included overall survival (OS), disease control rate, duration of therapy, and the frequency and severity of adverse events. This study enrolled 472 patients at 55 German sites. The median PFS was 8.3 months (95%CI 7.1\u20139.3) and the median OS was 18.3 months (14.9\u201321.3), both tending to be longer in pre-treated patients. In the 147 patients with CNS metastases, PFS was similar in those requiring corticosteroids (probably representing symptomatic patients, 5.6 months (3.9\u20137.2)) compared with those not requiring corticosteroids (5.9 months (4.8\u20136.9)); however, OS was shorter in patients with brain metastases who received corticosteroids (7.8 (6.3\u201311.6)) compared to those who did not (11.9 months (9.6\u201319.5)). The integrated subjective assessment of tumor growth dynamics proved helpful to predict outcome: investigators\u2019 upfront categorization correlated well with time-to-event outcomes. Taken together, COMBI-r mirrored PFS outcomes from other prospective, observational studies and confirmed efficacy and safety findings from the pivotal phase III COMBI-d\/-v and COMBI-mb trials.<\/jats:p>","DOI":"10.3390\/cancers15184436","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:23:42Z","timestamp":1693995822000},"page":"4436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"first","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen\u2014European Metropolitan Region N\u00fcrnberg, Friedrich-Alexander University (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK), Partner Site Essen, 45147 Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nuremberg General Hospital\u2014Paracelsus Medical University, 90419 Nuremberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Klinikum Bremen-Ost, Gesundheit Nord gGmbH, 28205 Bremen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-4961","authenticated-orcid":false,"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Cancer Center, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-1577","authenticated-orcid":false,"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Tuebingen, 72076 Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Kiecker","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Vivantes Klinikum Berlin Neuk\u00f6lln, 12351 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Elbe Kliniken Buxtehude, 21614 Buxtehude, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K.","family":"Eigentler","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Skin Cancer Center Charit\u00e9, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina","family":"Remy","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, 90429 Nuremberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Schober","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, 90429 Nuremberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-1825","authenticated-orcid":false,"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen\u2014European Metropolitan Region N\u00fcrnberg, Friedrich-Alexander University (FAU), 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imke","family":"von Wasielewski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK), Partner Site Essen, 45147 Essen, Germany"},{"name":"Comprehensive Cancer Center (Westdeutsches Tumorzentrum), University Hospital Essen, Essen & National Center for Tumor Diseases (NCT); NCT-West, Campus Essen & Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, 44801 Minden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T.F., Al Lami, F.H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., and Amini, E. (2018). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol., 4, 1553\u20131568.","DOI":"10.1200\/JCO.2018.36.15_suppl.1568"},{"key":"ref_6","unstructured":"Global Burden of Disease 2019 Cancer Collaboration, Kocarnik, J.M., Compton, K., Dean, F.E., Fu, W., Gaw, B.L., Harvey, J.D., Henrikson, H.J., Lu, D., and Pennini, A. (2022). Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups from 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol., 8, 420\u2013444."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab plus Ipilimumab or Nivolumab Alone versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41784188","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF V600-Mutant Melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1210","article-title":"Using Real-World Data to Extrapolate Evidence from Randomized Controlled Trials","volume":"105","author":"Wang","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: Partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-World Evidence\u2014What Is It and What Can It Tell Us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: A measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., G\u00f8tzsche, P.C., Vandenbroucke, J.P., and STROBE Initiative (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040296"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness","volume":"320","author":"Sacks","year":"2018","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"djx87","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world Data for Clinical Evidence Generation in Oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2021.05.031","article-title":"Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib","volume":"154","author":"Saiag","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CMR.0000000000000832","article-title":"Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors","volume":"32","author":"Ismail","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1007\/s10147-020-01737-3","article-title":"Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation","volume":"25","author":"Teshima","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CMR.0000000000000833","article-title":"Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: A noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study","volume":"32","author":"Meyer","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Atkinson, V.G., Quaglino, P., Aglietta, M., Del Vecchio, M., Depenni, R., Consoli, F., Bafaloukos, D., Ferrucci, P.F., Tulyte, S., and Krajsov\u00e1, I. (2021). A Retrospective Analysis of Dabrafenib and\/or Dabrafenib plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers, 13.","DOI":"10.3390\/cancers13102466"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11523-021-00850-1","article-title":"Retrospective Chart Review of Dabrafenib plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)","volume":"16","author":"Aglietta","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CMR.0000000000000654","article-title":"Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: Analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)","volume":"30","author":"Atkinson","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e21539","DOI":"10.1200\/JCO.2022.40.16_suppl.e21539","article-title":"Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data","volume":"40","author":"Czarnecka","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial","volume":"41","author":"Ascierto","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100398","DOI":"10.1016\/j.esmoop.2022.100398","article-title":"Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations","volume":"7","author":"Solomon","year":"2022","journal-title":"ESMO Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2019.08.032","article-title":"A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma","volume":"123","author":"Franken","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102083","DOI":"10.1016\/j.ctrv.2020.102083","article-title":"Melanoma brain metastases\u2014Interdisciplinary management recommendations 2020","volume":"89","author":"Gutzmer","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2022.07.035","article-title":"An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases","volume":"175","author":"Dutriaux","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-22-2581","article-title":"Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases","volume":"29","author":"Wilmott","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1158\/1078-0432.CCR-19-0287","article-title":"Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models","volume":"26","author":"Bruno","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.05.005","article-title":"Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","volume":"153","author":"Schadendorf","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/2168479013497033","article-title":"Legal Requirements, Definitions, and Standards for Non-interventional Drug Studies: A Global Picture of Variability-Results and Conclusions from a Single-Institution Survey","volume":"47","author":"Hartmann","year":"2013","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","article-title":"Bias and causal associations in observational research","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s43441-021-00328-2","article-title":"Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival","volume":"55","author":"Nakagawa","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40265-017-0728-y","article-title":"Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors","volume":"77","author":"Michiels","year":"2017","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kang, J., and Cairns, J. (2022). Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10350-8"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","article-title":"Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types","volume":"39","author":"Torres","year":"2022","journal-title":"Adv. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:52Z","timestamp":1760129152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":52,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15184436"],"URL":"https:\/\/doi.org\/10.3390\/cancers15184436","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}